The charts on this page feature a breakdown of the total annual pay for the top executives at CVS HEALTH Corp as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. CVS HEALTH Corp income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. CVS HEALTH Corp annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Larry J. Merlo
President and Chief Executive Officer
Total Cash $7,772,000 Equity $13,499,942 Other $667,156 Total Compensation $21,939,098
David M. Denton
Former Executive Vice President and Chief Financial Officer
Total Cash $781,818 Equity $3,999,928 Other $782,805 Total Compensation $5,564,551
Jonathan C. Roberts
Executive Vice President and Chief Operating Officer
Total Cash $4,089,500 Equity $11,749,911 Other $227,557 Total Compensation $16,066,968
Thomas M. Moriarty
Executive Vice President, Chief Policy and External Affairs Officer and General Counsel
Total Cash $2,906,500 Equity $7,999,926 Other $77,430 Total Compensation $10,983,856
Eva C. Boratto
Executive Vice President and Chief Financial Officer
Total Cash $1,794,503 Equity $5,099,828 Other $78,090 Total Compensation $6,972,421
Derica W. Rice
Executive Vice President and President -CVS Caremark
Total Cash $2,690,477 Equity $9,830,160 Other $285,436 Total Compensation $12,806,073
For its 2018 fiscal year, CVS HEALTH Corp, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Larry J. Merlo CEO Pay $21,953,040 Median Employee Pay $35,529 CEO Pay Ratio 618:1
For its 2018 fiscal year, CVS HEALTH Corp, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Alecia A. DeCoudreaux Total Cash $280,973
Anne M. Finucane Total Cash $280,000
C. David Brown, II Total Cash $302,043
David W. Dorman Total Cash $570,000
Jean-Pierre Millon Total Cash $282,043
Mary L. Schapiro Total Cash $280,000
Nancy-Ann M. DeParle Total Cash $280,000
Richard J. Swift Total Cash $307,043
Richard M. Bracken Total Cash $297,043
Tony L. White Total Cash $282,043
William C. Weldon Total Cash $280,000

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.